Top gastroenterology research from ACG 2016

Researchers presented data and clinical updates at the American College of Gastroenterology Annual Scientific Meeting. Live coverage from Las Vegas featured news from the conference, onsite video interviews with leading experts and research implications on patient care and practice.

Healio Internal Medicine presents the top seven gastroenterology stories from ACG 2016.

Remimazolam safe, effective for outpatient colonoscopy sedation

Remimazolam was a safe and effective agent for conscious sedation during outpatient colonoscopy in a multicenter randomized controlled trial, according to data. Read more.

Remicade prevents serious infection, longer hospitalization in ulcerative colitis vs. Humira

Patients with ulcerative colitis treated with Remicade were more likely to not experience serious infection or longer hospitalization compared with patients treated with Humira, according to a presentation from a plenary session. Read more.

Emend improves gastroparesis symptoms, fails to reach endpoint

Oral Emend improved gastroparesis symptoms based on commonly used gastroparesis measures in a randomized controlled trial, according to APRON results. Read more.

Naldemedine relieves opioid-induced constipation within 4 hours

Naldemedine induced spontaneous bowel movements more quickly than placebo — often within 4 hours of first dose — and maintained its efficacy for 12 weeks, according to data. Read more.

Xeljanz induces remission, early response predicts efficacy in ulcerative colitis

Xeljanz as induction therapy for patients with moderate-to-severe ulcerative colitis led to remission as early as 2 weeks; the early response rates correlated with efficacy results at 8 weeks, according to data from the OCTAVE induction trials. Read more.

Adults with eosinophilic esophagitis have positive long-term outcomes after diagnosis

Ten years after initial diagnosis of eosinophilic esophagitis, most adults with the disease have resolution of symptoms and minimal impacts on quality of life, according to a retrospective study. Read more.

Ozanimod shows long-term improvement in ulcerative colitis

Ozanimod therapy showed long-term efficacy through improved Mayo score, and decreased incidence of rectal bleeding and stool frequency in patients with moderate-to-severe ulcerative colitis, according to data from the TOUCHSTONE trial. Read more.